Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models

被引:45
作者
Leahy, David E. [1 ]
机构
[1] Cyprotex Discovery Ltd, Macclesfield SK10 2DR, Cheshire, England
关键词
ADME; animal alternative; PBPK; physiologically based pharmacokinetic modelling; predictive pharmacokinetics; risk assessment;
D O I
10.1517/17425255.2.4.619
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Early estimation of kinetics in man currently relies on extrapolation from experimental data generated in animals. Recent results from the application of a generic physiologically based model, Cloe PK (R) (Cyprotex), which is parameterised for human and rat physiology, to the estimation of plasma pharmacokinetics, are summarised in this paper. A comparison with predictive methods that involve scaling from in vivo animal data can also be made from recently published data. On average, the divergence of the predicted plasma concentrations from the observed data was 0.47 log units. For the external test set, > 70% of the predicted values of the AUC were within threefold of the observed values. Furthermore, the model was found to match or exceed the performance of three published interspecies scaling methods for estimating clearance, all of which showed a distinct bias towards overprediction. It is concluded that Cloe PK, as a means of integrating readily determined in vitro arid/or in silico data, is a powerful, cost-effective tool for estimating exposure and kinetics in drug discovery and risk assessment that should, if widely adopted, lead to major reductions in the need for animal experimentation.
引用
收藏
页码:619 / 628
页数:10
相关论文
共 20 条
  • [1] PHYSIOLOGICAL MODELING OF CYCLOSPORINE KINETICS IN RAT AND MAN
    BERNAREGGI, A
    ROWLAND, M
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (01): : 21 - 50
  • [2] Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma
    Brightman, FA
    Leahy, DE
    Searle, GE
    Thomas, S
    [J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (01) : 84 - 93
  • [3] Brightman FA, 2006, DRUG METAB DISPOS, V34, P94, DOI 10.1124/dmd.105.004838
  • [4] Allometric scaling of pharmacokinetic parameters in drug discovery:: Can human CL, VSS and t1/2 be predicted from in-vivo rat data?
    Caldwell, GW
    Masucci, JA
    Yan, ZY
    Hageman, W
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2004, 29 (02) : 133 - 143
  • [5] QUANTIFICATION OF BIOLOGICAL VARIABILITY
    DROZ, PO
    [J]. ANNALS OF OCCUPATIONAL HYGIENE, 1992, 36 (03) : 295 - 306
  • [6] Physiologically-based pharmacokinetic simulation modelling
    Grass, GM
    Sinko, PJ
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (03) : 433 - 451
  • [7] Within- and between-subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects
    Hanna, J
    Foster, DJR
    Salter, A
    Somogyi, AA
    White, JM
    Bochner, F
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) : 404 - 413
  • [8] KOMIYA I, 1986, DRUG METAB DISPOS, V14, P239
  • [9] Leahy, 2004, BIOSILICO, V2, P78
  • [10] Progress in simulation modelling for pharmacokinetics
    Leahy, DE
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (11) : 1257 - 1268